FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022034472> ?p ?o ?g. }

• W2022034472 endingPage "1656" @default.
• W2022034472 startingPage "1650" @default.
• W2022034472 abstract "Infiltrating pleomorphic lobular carcinoma (PLC) is an aggressive variant of infiltrating lobular carcinoma. Recently, in situ changes identical to PLC (PLCIS) have been described. The role of prognostic markers and their correlation with therapeutics, clinical outcome, and genetic changes is not well established in PLC. The authors examined 38 cases of this entity to understand better this tumor's biology. Immunohistochemical (IHC) analysis was performed in 21 specimens for estrogen and progesterone steroid receptors, p53, Her 2 (p185), and GCDFP-15. Genomic deoxyribonucleic acid was obtained from microdissected tumor as well as normal control cells, and loss of heterozygosity was investigated at the ESR (16q24), p53 (TP53 17p), Her 2 (17q 11-12), and BRCA 1 (17q12-25) loci. In this series, the average patient age was 57.5 years (age range, 24-92 years). Twenty-seven women were postmenopausal. Tumor size ranged from 1.2 to 25 cm. Six patients were a pathologic stage I; 19, stage II; 12, stage III; and one, stage IV. Histologically, multifocal nodular aggregates of discohesive pleomorphic tumor cells were seen interspersed in dense and fibrotic breast parenchyma. Twenty-nine percent of the specimens demonstrated associated signet ring cells. The remainder had dishesive, globoid, plasmacytoid cells with high-grade nuclear features. PLCIS was identified in 17 of 38 patients (45%), and lobular carcinoma in situ (LCIS) was noted in 8 patients (21%). IHC analysis showed estrogen immunoreactivity in 81%, progesterone in 67%, GCDFP-15 in 71%, and Her 2 in 81% (2+ to 3+ membranous staining) of specimens. Antibodies to p53 stained the tumor cell nuclei in 48% of the tumors. Loss of heterozygosity was identified in 52% of the specimens at the p53 locus, 18% at the ESR locus, 19% to 24% at the Her 2 loci, and 27% to 32% at the BRCA 1 locus. Follow-up was available in 19 patients and ranged from 12 months to 15 years (mean, 73 months). Seven patients had no evidence of disease at last examination (range, 1-15 years), three patients were alive with disease (range, 2-14 years), and nine patients were dead of disease (range, 2 months-9 years). Six patients had subsequent diagnoses of tumor in the contralateral breast. Analysis shows that PLC tends to appear in older postmenopausal women who present with locally advanced disease. PLCIS was found to be associated with PLC 45% of the time. The aggressive clinical course of patients with PLC is supported by tumor immunoreactivity with unfavorable markers Her 2 and p53. Overexpression of Her 2 in PLC may be therapeutically relevant, enabling the use of novel chemotherapeutic drugs like Herceptin. Interestingly, tumors that were Her 2 immunoreactive also maintained estrogen hormone immunoreactivity." @default.
• W2022034472 created "2016-06-24" @default.
• W2022034472 creator A5004216010 @default.
• W2022034472 creator A5024598099 @default.
• W2022034472 creator A5032917209 @default.
• W2022034472 creator A5035792015 @default.
• W2022034472 creator A5040707006 @default.
• W2022034472 creator A5054146741 @default.
• W2022034472 date "2000-12-01" @default.
• W2022034472 modified "2023-10-01" @default.
• W2022034472 title "Pleomorphic Lobular Carcinoma: Morphology, Immunohistochemistry, and Molecular Analysis" @default.
• W2022034472 cites W1976865668 @default.
• W2022034472 cites W1977285497 @default.
• W2022034472 cites W1977709872 @default.
• W2022034472 cites W1979734182 @default.
• W2022034472 cites W1981488582 @default.
• W2022034472 cites W1994934750 @default.
• W2022034472 cites W1996311544 @default.
• W2022034472 cites W2015083079 @default.
• W2022034472 cites W202532301 @default.
• W2022034472 cites W2026788714 @default.
• W2022034472 cites W2027472658 @default.
• W2022034472 cites W2035318542 @default.
• W2022034472 cites W2044066504 @default.
• W2022034472 cites W2056314019 @default.
• W2022034472 cites W2060608010 @default.
• W2022034472 cites W2062327031 @default.
• W2022034472 cites W2071600126 @default.
• W2022034472 cites W2086461593 @default.
• W2022034472 cites W2126163615 @default.
• W2022034472 cites W2135485202 @default.
• W2022034472 cites W2138436911 @default.
• W2022034472 cites W2291927913 @default.
• W2022034472 doi "https://doi.org/10.1097/00000478-200012000-00009" @default.
• W2022034472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11117786" @default.
• W2022034472 hasPublicationYear "2000" @default.
• W2022034472 type Work @default.
• W2022034472 sameAs 2022034472 @default.
• W2022034472 citedByCount "178" @default.
• W2022034472 countsByYear W20220344722012 @default.
• W2022034472 countsByYear W20220344722013 @default.
• W2022034472 countsByYear W20220344722014 @default.
• W2022034472 countsByYear W20220344722015 @default.
• W2022034472 countsByYear W20220344722016 @default.
• W2022034472 countsByYear W20220344722017 @default.
• W2022034472 countsByYear W20220344722018 @default.
• W2022034472 countsByYear W20220344722019 @default.
• W2022034472 countsByYear W20220344722020 @default.
• W2022034472 countsByYear W20220344722021 @default.
• W2022034472 countsByYear W20220344722022 @default.
• W2022034472 countsByYear W20220344722023 @default.
• W2022034472 crossrefType "journal-article" @default.
• W2022034472 hasAuthorship W2022034472A5004216010 @default.
• W2022034472 hasAuthorship W2022034472A5024598099 @default.
• W2022034472 hasAuthorship W2022034472A5032917209 @default.
• W2022034472 hasAuthorship W2022034472A5035792015 @default.
• W2022034472 hasAuthorship W2022034472A5040707006 @default.
• W2022034472 hasAuthorship W2022034472A5054146741 @default.
• W2022034472 hasConcept C104317684 @default.
• W2022034472 hasConcept C121608353 @default.
• W2022034472 hasConcept C126322002 @default.
• W2022034472 hasConcept C142724271 @default.
• W2022034472 hasConcept C143589142 @default.
• W2022034472 hasConcept C180754005 @default.
• W2022034472 hasConcept C204232928 @default.
• W2022034472 hasConcept C2777546739 @default.
• W2022034472 hasConcept C2779296616 @default.
• W2022034472 hasConcept C2780862961 @default.
• W2022034472 hasConcept C3018521938 @default.
• W2022034472 hasConcept C530470458 @default.
• W2022034472 hasConcept C55493867 @default.
• W2022034472 hasConcept C71924100 @default.
• W2022034472 hasConcept C84606932 @default.
• W2022034472 hasConcept C86803240 @default.
• W2022034472 hasConceptScore W2022034472C104317684 @default.
• W2022034472 hasConceptScore W2022034472C121608353 @default.
• W2022034472 hasConceptScore W2022034472C126322002 @default.
• W2022034472 hasConceptScore W2022034472C142724271 @default.
• W2022034472 hasConceptScore W2022034472C143589142 @default.
• W2022034472 hasConceptScore W2022034472C180754005 @default.
• W2022034472 hasConceptScore W2022034472C204232928 @default.
• W2022034472 hasConceptScore W2022034472C2777546739 @default.
• W2022034472 hasConceptScore W2022034472C2779296616 @default.
• W2022034472 hasConceptScore W2022034472C2780862961 @default.
• W2022034472 hasConceptScore W2022034472C3018521938 @default.
• W2022034472 hasConceptScore W2022034472C530470458 @default.
• W2022034472 hasConceptScore W2022034472C55493867 @default.
• W2022034472 hasConceptScore W2022034472C71924100 @default.
• W2022034472 hasConceptScore W2022034472C84606932 @default.
• W2022034472 hasConceptScore W2022034472C86803240 @default.
• W2022034472 hasIssue "12" @default.
• W2022034472 hasLocation W20220344721 @default.
• W2022034472 hasLocation W20220344722 @default.
• W2022034472 hasOpenAccess W2022034472 @default.
• W2022034472 hasPrimaryLocation W20220344721 @default.
• W2022034472 hasRelatedWork W1970614368 @default.
• W2022034472 hasRelatedWork W2085896209 @default.
• W2022034472 hasRelatedWork W2144330460 @default.

• next